The global breast biopsy market is projected to reach USD 3,261.7 million by 2030, growing from USD 2,384.1 million in 2025, at a CAGR of 6.5% during the forecast period (2025–2030). This growth is driven by the increasing global incidence of breast cancer, rising awareness about early detection, and the growing demand for minimally invasive and non-invasive diagnostic procedures that improve patient comfort and shorten recovery times.
Rising Breast Cancer Prevalence Fuels Market Growth
Breast cancer remains one of the most commonly diagnosed cancers among women worldwide. The growing number of cases has made early and accurate diagnosis essential, leading to a surge in demand for breast biopsy devices. Modern imaging modalities such as 3D mammography, digital breast tomosynthesis, and ultrasound-guided biopsy systems have significantly advanced diagnostic accuracy.
Governments and healthcare organizations across developed and emerging markets are actively implementing breast cancer screening programs to detect cancer at earlier stages. These initiatives, combined with growing public awareness and improvements in healthcare infrastructure, are driving consistent growth in the breast biopsy market.
Technological Advancements and Patient-Centric Innovations
Technological innovation is at the core of the expanding breast biopsy devices market. The shift toward minimally invasive biopsy techniques, such as core needle biopsy (CNB) and vacuum-assisted biopsy (VAB), has gained strong clinical acceptance due to their precision, safety, and patient comfort compared to traditional surgical biopsies.
Furthermore, continuous advancements in imaging technologies—such as the integration of ultrasound, MRI, and CT—enable physicians to obtain high-quality tissue samples for accurate pathological assessment. These innovations reduce procedure time and recovery duration, aligning with the growing trend toward outpatient and ambulatory care settings.
Key Market Drivers
- Increasing Global Incidence of Breast Cancer:
The growing number of breast cancer cases globally continues to be a major driver of the breast biopsy market. - Adoption of Early Diagnostic Screening Programs:
National health agencies and private healthcare institutions are emphasizing preventive healthcare and encouraging women to undergo regular breast screening. - Advancements in Minimally Invasive Biopsy Technologies:
Techniques such as image-guided and vacuum-assisted systems are improving diagnostic precision and reducing patient discomfort. - Expansion of Healthcare Infrastructure in Emerging Markets:
Countries in Asia-Pacific and Latin America are investing in healthcare facilities and diagnostic technologies, opening new opportunities for market players. - Supportive Government Initiatives and Reimbursement Policies:
In developed regions such as North America and Europe, favorable reimbursement frameworks and awareness campaigns are helping increase access to advanced biopsy procedures.
Segmentation Insights
By Product: Biopsy Needles Lead the Growth
The breast biopsy devices market is categorized into biopsy needles, biopsy equipment, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other products. Among these, the biopsy needles segment is expected to record the highest CAGR during the forecast period.
Biopsy needles play a vital role in minimally invasive diagnostic procedures like core needle biopsy (CNB) and fine needle aspiration biopsy (FNAB). These devices offer faster recovery, minimal scarring, and reduced procedural discomfort. Continuous product innovations—such as vacuum-assisted and ultrasound-assisted biopsy needles—and the integration of imaging capabilities enhance diagnostic efficiency and accuracy, driving widespread adoption across clinical settings.
By Procedure: Liquid Biopsy Shows Remarkable Potential
Based on procedure, the market is divided into needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. The liquid breast biopsy segment is anticipated to grow at a significant rate over the forecast period due to its non-invasive nature and ability to deliver real-time molecular insights into tumor dynamics.
Liquid biopsies analyze circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood samples, allowing clinicians to monitor treatment response, identify genetic mutations, and detect recurrence early. This technology provides a promising alternative to traditional tissue biopsies, particularly in cases where surgery may pose higher risks.
By Application: Early Cancer Screening Dominates
In 2024, the early cancer screening segment accounted for the largest share of the global breast biopsy market. Growing emphasis on early detection, fueled by advanced imaging technologies such as AI-assisted mammography and genetic risk assessment, is driving this segment’s dominance.
Public health campaigns and improved accessibility to diagnostic tools have led to higher participation rates in regular screenings. These efforts, supported by government initiatives and healthcare organizations, are expected to further boost the adoption of early screening programs worldwide.
By End User: Hospitals & Surgical Centers Hold the Largest Share
Among end users, hospitals and surgical centers represent the largest market share. Their dominance is attributed to advanced diagnostic infrastructure, trained medical professionals, and access to cutting-edge imaging systems, including digital mammography, MRI, and ultrasound.
The increasing patient preference for integrated care and quick diagnostic turnaround also makes hospitals and surgical centers a preferred choice for breast biopsy procedures. However, specialized breast care centers and diagnostic imaging clinics are expected to grow steadily due to their cost-effectiveness and convenience.
Regional Insights: North America Leads the Global Market
Geographically, the breast biopsy devices market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America held the largest market share in 2024 and is expected to maintain its lead through 2030. The region’s dominance is fueled by its well-established healthcare infrastructure, high healthcare expenditure, and early adoption of advanced biopsy technologies.
In the United States, high awareness levels and the prevalence of breast cancer are driving demand for accurate diagnostic solutions. Government initiatives, such as the Breast and Cervical Cancer Mortality Prevention Act, are improving access to screening and diagnostic services, particularly among low-income populations.
Meanwhile, the Asia Pacific region is emerging as a high-growth market due to improving diagnostic facilities, increasing government investment in healthcare, and a growing emphasis on women’s health awareness programs.
Key Market Players
The global breast biopsy market features several prominent players actively innovating and expanding their product portfolios. Major companies include:
- Hologic, Inc. (US)
- Danaher Corporation (US)
- Becton, Dickinson and Company (US)
- Argon Medical Devices, Inc. (US)
- Merit Medical Systems (US)
- Menarini-Silicon Biosystems (Italy)
These companies are focusing on product innovation, strategic partnerships, and expansion into emerging markets to strengthen their presence globally.
Conclusion
The breast biopsy market is evolving rapidly with advancements in diagnostic imaging, minimally invasive techniques, and molecular testing. As healthcare systems continue to prioritize early detection and precision medicine, the demand for efficient and patient-friendly biopsy solutions will continue to rise. With robust growth prospects and expanding access to advanced diagnostic care, the market is set to witness substantial progress through 2030.